Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

A Bonaventura, A Vecchié, L Dagna… - Nature Reviews …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe …

Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?

V Bajaj, N Gadi, AP Spihlman, SC Wu, CH Choi… - Frontiers in …, 2021 - frontiersin.org
The novel coronavirus severe acute respiratory syndrome coronavirus 2 causing the
Coronavirus disease (COVID-19) pandemic has ravaged the world with over 72 million total …

COVID-19: Discovery, diagnostics and drug development

T Asselah, D Durantel, E Pasmant, G Lau… - Journal of …, 2021 - Elsevier
Summary Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019,
and has since become a pandemic. Groups from China identified and sequenced the virus …

Drug repurposing approach to fight COVID-19

TU Singh, S Parida, MC Lingaraju, M Kesavan… - Pharmacological …, 2020 - Springer
Currently, there are no treatment options available for the deadly contagious disease,
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …

COVID-19: A review of therapeutic strategies and vaccine candidates

V Izda, MA Jeffries, AH Sawalha - Clinical Immunology, 2021 - Elsevier
The world is engulfed by one of the most widespread and significant public health crises in
decades as COVID-19 has become among the leading causes of death internationally. The …

Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway …

H Zhu, Z Jian, Y Zhong, Y Ye, Y Zhang, X Hu… - Frontiers in …, 2021 - frontiersin.org
Background Inflammatory responses play a multiphase role in the pathogenesis of cerebral
ischemic stroke (IS). Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces …

Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection

N Desai, A Neyaz, A Szabolcs, AR Shih… - Nature …, 2020 - nature.com
The relationship of SARS-CoV-2 pulmonary infection and severity of disease is not fully
understood. Here we show analysis of autopsy specimens from 24 patients who succumbed …

Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19

I Bernard, D Limonta, LK Mahal, TC Hobman - Viruses, 2020 - mdpi.com
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2) poses a persistent threat to global public …

BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies

K Herzog Tzarfati, O Gutwein, A Apel… - American Journal of …, 2021 - Wiley Online Library
Patients with hematologic malignancies have an increased risk of severe COVID‐19
infection. Vaccination against COVID‐19 is especially important in these patients, but …

COVID-19-associated opportunistic infections: a snapshot on the current reports

A Abdoli, S Falahi, A Kenarkoohi - Clinical and experimental medicine, 2022 - Springer
Abstract Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a
complicated challenge, especially among patients with severe disease. In recent studies …